Acute Myeloid Leukemia Post Cytotoxic Therapy

Acute Myeloid Leukemia Post Cytotoxic Therapy — Trials · CancerIndex

Clinical trials

Registered studies

55 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 17
Recruiting: 6
Ph III recruiting: 0
Growth YoY: —
Industry share: 6%
Top sponsor: National Cancer Institute (NCI)
Termination share: 19.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (6)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02381548	Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia	terminated	Phase 1	20	National Cancer Institute (NCI)NIH	1	Jan 30, 2026	clinicaltrials
NCT01640301	Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant	terminated	Phase 1 / Phase 2	47	Fred Hutchinson Cancer CenterOTHER